<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946556</url>
  </required_header>
  <id_info>
    <org_study_id>HET-85518</org_study_id>
    <nct_id>NCT00946556</nct_id>
  </id_info>
  <brief_title>Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix</brief_title>
  <official_title>Examining the Ability of HSV2 Therapy to Reduce HIV Target Cell Numbers in the Cervix.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Herpes simplex virus type 2 (HSV2), the most common cause of genital herpes, increases a
      woman's risk of HIV acquisition from 3-6 fold, perhaps because HSV2-infected women have
      increased numbers of HIV &quot;target cells&quot; (CD4 T cells and dendritic cells) in the cervical
      mucosa. However, recent clinical trials showed no impact of HSV2 suppression on HIV
      acquisition rates. The reasons for this negative result are unclear. The investigators
      propose to examine the effect of valacyclovir (a widely used herpes medication) treatment on
      cervical immunology and HIV target cells in the cervix. The study will take the form of a
      randomized, double-blind, placebo-controlled crossover trial. Primary endpoints will be (1)
      the number of CD4 T cells on a cervical cytobrush and (2) the number of immature dendritic
      cells per cervical cytobrush.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CD4+ T cells on a cervical cytobrush.</measure>
    <time_frame>Monthly intervals for 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of immature dendritic cells on a cervical cytobrush</measure>
    <time_frame>Monthly intervals for 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proinflammatory cytokine/chemokine levels in cervicovaginal secretions</measure>
    <time_frame>Monthly intervals for 5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Herpes Simplex Type Two Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>1g po od for 2 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo po od for 2 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Valacyclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  HSV2 infected

        Exclusion Criteria:

          -  HIV infected

          -  Pregnant

          -  Taking HSV2 therapy

          -  Current/recent (past 3 months) genital infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Kaul, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health In Women's Hands</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007 Mar 12;21(5):589-98.</citation>
    <PMID>17314521</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Rupert Kaul</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>herpes simplex virus type 2</keyword>
  <keyword>HIV</keyword>
  <keyword>genital immunology</keyword>
  <keyword>CD4+ T cell</keyword>
  <keyword>valacyclovir</keyword>
  <keyword>HIV seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 6, 2016</submitted>
    <returned>October 26, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

